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Contemporary incidence and risk factors of
post transplant Erythrocytosis in deceased
donor kidney transplantation
Sami Alasfar1,2*, Isaac E. Hall3, Sherry G. Mansour4,5, Yaqi Jia1, Heather R. Thiessen-Philbrook1, Francis L. Weng6,
Pooja Singh7, Bernd Schröppel8, Thangamani Muthukumar9,10, Sumit Mohan11,12, Rubab F. Malik1,
Meera N. Harhay13,14, Mona D. Doshi15, Enver Akalin16, Jonathan S. Bromberg17,18, Daniel C. Brennan1,
Peter P. Reese19,20,21 and Chirag R. Parikh1

Abstract
Background: Post-Transplant erythrocytosis (PTE) has not been studied in large recent cohorts. In this study, we
evaluated the incidence, risk factors, and outcome of PTE with current transplant practices using the present World
Health Organization criteria to define erythrocytosis. We also tested the hypothesis that the risk of PTE is greater
with higher-quality kidneys.
Methods: We utilized the Deceased Donor Study which is an ongoing, multicenter, observational study of
deceased donors and their kidney recipients that were transplanted between 2010 and 2013 across 13 centers.
Eryrthocytosis is defined by hemoglobin> 16.5 g/dL in men and> 16 g/dL in women. Kidney quality is measured by
Kidney Donor Profile Index (KDPI).
Results: Of the 1123 recipients qualified to be in this study, PTE was observed at a median of 18 months in 75
(6.6%) recipients. Compared to recipients without PTE, those with PTE were younger [mean 48±11 vs 54±13 years, p
< 0.001], more likely to have polycystic kidney disease [17% vs 6%, p < 0.001], have received kidneys from younger
donors [36 ±13 vs 41±15 years], and be on RAAS inhibitors [35% vs 22%, p < 0.001]. Recipients with PTE were less
likely to have received kidneys from donors with hypertension [16% vs 32%, p = 0.004], diabetes [1% vs 11%, p =
0.008], and cerebrovascular event (24% vs 36%, p = 0.036). Higher KDPI was associated with decreased PTE risk [HR
0.98 (95% CI: 0.97–0.99)]. Over 60 months of follow-up, only 17 (36%) recipients had sustained PTE. There was no
association between PTE and graft failure or mortality,
Conclusions: The incidence of PTE was low in our study and PTE resolved in majority of patients. Lower KDPI
increases risk of PTE. The underutilization of RAAS inhibitors in PTE patients raises the possibility of underrecognition of this phenomenon and should be explored in future studies.
Keywords: Erythrocytosis, Kidney transplant, Hemoglobin, KDPI
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Background
Post-transplant erythrocytosis (PTE) has a reported incidence between 8 and 20% and is a potentially serious
complication following kidney transplantation (KT) with
increased morbidity and risk for thromboembolic events
[1–7]. Several studies have assessed the incidence, risk
factors, and impact of PTE on outcomes following KT
[1–10]; however, reports about PTE in the background
of modern immunosuppression are lacking. In addition,
previously published studies have several limitations.
Most of these studies lacked standardized definition of PTE.
Some studies used cut off values of hematocrit (50 to 53.5%),
or hemoglobin (16.5–18 g/dL), whereas others used a cut off
value of actual red cell mass [1–5, 7–9, 11–13]. Despite the
variation in normal hemoglobin values between men and
women, some studies and guidelines, including KDIGO 2009
guidelines, used the same threshold to define PTE in both
sexes while others used separate sex-based cutoffs [14]. The
duration of erythrocytosis in prior studies has also been variable with some including all patients above the cutoff value at
any time after transplantation, whereas others required persistence of PTE beyond a set period of time. Most of the prior
studies have been from single centers and included patients
who were transplanted before the adoption of T-cell depleting
induction immunosuppression and mycophenolate for maintenance. These newer agents can cause significant bone marrow suppression and may potentially reduce the incidence of
PTE. In addition, some studies have suggested that PTE is
more common in KT recipients with well-preserved renal
allograft function [6, 9] and in recipients of simultaneous pancreas and KT, which could be explained by the favorable
donor quality that these recipients enjoy [13].
In 2016, the World Health Organization (WHO) revised the cutoff values for diagnosing erythrocytosis to
include hemoglobin > 16.5 g/dL in men and > 16 g/dL in
women, hematocrit > 49% in men and > 48% in women,
or red cell mass > 25% above the mean normal predicted
value [15, 16]. These are lower values than previously
used to define PTE. As there are no large multicenter
studies of PTE in the modern era of immunosuppression, we utilized the ongoing Deceased Donor Study
(DDS) cohort to evaluate the incidence and risk factors
of PTE with current transplant practices and using the
present WHO approved definition. We also tested the
hypothesis that the risk of PTE is greater with higherquality kidneys [i.e., lower kidney donor profile index
(KDPI)] in deceased-donor KT and assessed the impact
of PTE on patient and allograft outcome.
Methods
Study cohort

The study cohort is derived from the Deceased Donor
Study (DDS), which is an ongoing multicenter, observational, cohort of deceased donors and their kidney
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recipients [17–20]. Briefly, five organ procurement organizations (OPOs) enrolled donors between May 2010
and December 2013 and followed their own protocols
for research authorization and donor management. Clinical variables were abstracted from OPO charts. We performed chart reviews for the subset of recipients at 13
participating transplant centers in our study network
who received kidneys from enrolled donors. Trained site
coordinators reviewed medical records and recorded detailed recipient characteristics, treatments, and outcomes. Data including hemoglobin measurements were
abstracted at month 3, 6, 12, 18, 24, 30, 36, 48, and 60.
Study staff at the data-coordinating center validated abstracted data to confirm data quality and accuracy (Supplementary Appendix A). Data for all kidney recipients
and donors were also obtained from the Organ Procurement and Transplantation Network (OPTN). The OPTN
data system includes data on all donors, wait-listed candidates, and transplant recipients in the United States,
submitted by the members of the OPTN, and is described more fully elsewhere [21]. The Health Resources
and Services Administration, US Department of Health
and Human Services provides oversight of the activities
of the OPTN. The current analyses are based on OPTN
data as of December 31, 2018. The OPO scientific review committees and the institutional review boards for
participating investigators approved the study. The
methods and conduct of this research study were consistent with the Principles of the Declaration of Istanbul
as outlined in the Declaration of Istanbul on Organ
Trafficking and Transplant Tourism.
Study variables

PTE was defined as having at least one measurement of
hemoglobin > 16.5 g/dL in men and > 16 g/dL in women
during the 5 years follow-up after transplant. Persistent
PTE was defined as having at least two qualifying measurements of hemoglobin. Every recipient had
hemoglobin abstracted from clinical charts at each time
point (3, 6, 12, 18, 24, 30, 36, 48, 60 months) regardless
whether the patient qualifies for PTE or not, eliminating
any lead-time bias. Diagnosis of PTE was based on laboratory criteria and not based on documentation of
PTE diagnosis in clinical chart. Possible causes of secondary erythrocytosis were not available in the abstracted data. Baseline characteristics were collected at
the time of transplant per the DDS protocol. The primary outcome of interest is PTE up to 5 years after
transplant and the time to first diagnosis of PTE. The
secondary outcomes include death-censored graft failure,
death only, or all-cause graft failure with median posttransplant follow-up of 4 (IQR = 3,5) years. Death censored graft failure was defined as primary non-function
of kidney after transplant, re-transplantation, or return
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to dialysis during follow-up time before death. Death
only was defined as all-cause mortality before graft failure. All-cause graft failure was defined as all-cause mortality, primary non-function, return to dialysis, or retransplantation.
We used KDPI as the primary exposure. KDPI is derived from the kidney donor risk index (KDRI), which is
calculated using the 10-variable equation generated by
Rao, et al. [22]. The variables are comprised by the following donor characteristics: age, height, weight, ethnicity, history of hypertension, history of diabetes, cause of
death, serum creatinine, hepatitis c virus sero-status
from serological or nucleic acid testing, and donation
after circulatory death (DCD) status. The KDPI represents a mapping of the KDRI, a measure of relative risk
of allograft failure, to a cumulative percentage scale [23].
We calculated the KDPI relative to all deceased donors
in the OPTN database in 2010.
Statistical analyses

We reported descriptive statistics as means (standard deviation) or medians (inter-quartile range) for continuous
variables, and frequencies (percentages) for categorical
variables. Continuous variables were compared with
Wilcoxon rank sum or Kruskal-Wallis tests, and categorical variables were compared with chi-square tests or
Fisher exact tests. Cox proportional hazards models were
used to evaluate the association between KDPI and the
outcome of PTE. We accounted for the cluster effect of
paired kidneys from the same donor using robust sandwich estimates We used Kolmogorov-type supremum
tests to evaluate proportional hazards assumptions [24].
We also explored the association of PTE with each secondary outcomes using time-varying covariate Cox
model [24]. For the time varying analysis, in recipients
that developed PTE, the time from transplant to PTE
diagnosis contributes to the non-event. The time from
PTE to last follow-up (5 years or death) contributes as
an event. The models adjusted for donor Kidney Donor
Profile Index (KDPI), cold ischemia time, transplant center, and the following recipient variables: age (years),
black race, sex, previous KT, number of human leukocytes antigen (HLA) mismatches, panel reactive antibody
(%), body mass index (BMI) (kg/m2), and preemptive
transplant. We conducted a complete case analysis because < 2% of data for all covariates was missing. SAS
9.4 software for Windows (SAS Institute, Cary, NC) was
used for all analyses. All statistical tests and confidence
intervals were 2-sided with a significance level of 0.05.

Results
Clinical characteristics

Fourteen recipients were excluded from the 1137 due to
missing hemoglobin or KDPI data, leaving the study
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cohort of 1123 patients. The median follow-up time was
60 (36, 60) months. PTE was observed in 75 (6.6%) patients and the median time to development of PTE was
18 months (18, 24). Mean peak hemoglobin in patients
with PTE was 17.12 ± 0.77 compared to 13.32 ±1.79 in
patients without PTE (p < 0.001).
Table 1 shows clinical characteristics of recipients with
and without PTE as well as their donors.
Compared to recipients without PTE, those with PTE
were younger [mean age 48 (11.2) vs 54 (13.3) years, p <
0.001], and more likely to have polycystic kidney disease
(PKD) as the cause of their end stage renal disease [17%
versus 6%, p < 0.001].
Immunosuppression regimen and other drugs

Anti-thymocyte globulin [rabbit] and basiliximab were
used for induction immunosuppression in 928 (83%) and
163 (15%) of recipients, respectively. Triple maintenance
immunosuppression regimen consisting of a calcineurin
inhibitor, mycopthenolate and prednisone was utilized in
82% of recipients. There was no difference in the choice of
induction or maintenance immunosuppression at discharge, 12 months, and 24 months after transplant between those with and without PTE (Table 2).
The average daily mycophenolate dose in the first 12
and 24 months following KT between PTE and non-PTE
groups was similar [1206 (446) versus 1185 (483) mg, p
= 0.86]. However, the average daily dose of tacrolimus
was lower in the PTE group at 12 months [6.7 (4.0) versus 8.1 (4.9) mg, p = 0.01] and at 24 months [6.0 (3.5)
versus 8.3 (3.1) mg, p = 0.007]. Renin-angiotensinaldosterone system (RAAS) inhibitors were prescribed in
182 (16%) and 257 (23%) of the recipients in this cohort
within 12 and 24 months following KT respectively.
Within the first 12 months, 24% of those with PTE were
on RAAS inhibitors during at least one follow-up visit
compared to 16% of those without PTE (p = 0.05).
Within the first 24 months, 35% of recipients with PTE
were on RAAS inhibitors at some point compared to
22% of those without PTE (p = 0.01). Regarding the timing of starting RAAS inhibitors, 31 (41%) of patients
with PTE were started on RAAS inhibitors after meeting
criteria for PTE and 10 (13%) were already on RAAS inhibition at the time they met criteria for PTE. This
leaves 34 (45%) patients with PTE who did not receive
any RAAS inhibitors despite meeting criteria for PTE.
KDPI and risk of PTE

Figure 1 demonstrates the cumulative incidence of PTE
by median KDPI category (< 50 versus ≥50) in the posttransplant period.
Recipients of kidneys with KDPI ≥50% were less likely
to develop PTE [HR 0.48 (0.29–0.78)]. We also observed
a continuum of risk across the KDPI score such that,
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Table 1 Clinical characteristics of recipients with and without Post Transplant Erythrocytosis
ALL (n = 1123)

No PTE (n = 1048)

PTE (n = 75)

P value

Mean age (Years)

53.6 (13.2)

54.0 (13.2)

48.3 (11.1)

< 0.001

African American race

524 (47%)

496 (47%)

28 (37%)

0.09

Mean BMI (kg/m2)

28.3 (5.6)

28.4 (5.6)

27.2 (5.5)

0.06

Clinical Variable
Recipients Characteristics

Gender (Male)
Cause of ESRD

687 (61%)

628 (60%)

59 (79%)

0.001

Diabetes

355 (32%)

330 (31%)

25 (33%)

< 0.001

Hypertension

313 (28%)

294 (28%)

19 (25%)

Glomerulonephritis

182 (16%)

171 (16%)

11 (15%)

PKD

67 (6%)

54 (6%)

13 (17%)

Graft failure

91 (8%)

87 (8%)

4 (5%)

Other or unknown

115 (6%)

54 (5%)

13 (17%)

Mean dialysis vintage (Months)a

53.4 (43.5)

53.6 (44.0)

51.2 (35.9)

History of prior KT

158 (14%)

151 (14%)

7 (9%)

0.22

Mean number of Human Leukocyte Antigen (HLA) mismatches (A,B,DR)

4.37 (1.33)

4.38 (1.34)

4.21 (1.08)

0.07

Mean calculated PRA

21.0 (35)

21.5 (35.3)

14.2 (29.1)

0.14

Mean age (Years)

41.5 (15.3)

41.9 (15.3)

36.32 (13.6)

0.002

African American race

179 (16%)

167 (16%)

12 (16%)

0.98

0.86

Donor Characteristics

Mean height (cm)

170.7 (11.1)

170.5 (11.2)

173.9 (9.7)

0.02

Mean weight (kg)

82.5 (22.3)

82.5 (22.4)

82.1 (20.0)

0.76

History of diabetes

117 (10%)

116 (11%)

1 (1%)

0.008

History of hypertension

347 (31%)

335 (32%)

12 (16%)

0.004

Donation after circulatory death (DCD)

215 (19%)

199 (19%)

16 (21%)

0.61

History of hepatitis C

30 (3%)

26 (2%)

4 (5%)

0.13

Cerebrovascular death

395 (35%)

377 (36%)

18 (24%)

0.03

Mean terminal serum creatinine (mg/dL)

1.21 (0.93)

1.2 (0.9)

1.31 (1.37)

0.82

Continuous variables: Wilcoxon rank sum or Kruskal-Wallis tests, and categorical variables were compared with chi-square tests or Fisher exact tests
BMI Body Mass Index, PKD Polycystic Kidney Disease, ESRD End Stage Renal Disease
a
For non-preemptive KT

higher KDPI was associated with lower risk of PTE [HR
0.98 (0.97–0.99)] (Fig. 2).
Among components of KDPI, donor age, height,
history of diabetes, history of hypertension, and cerebrovascular death as the cause of death were significantly different between PTE and non-PTE groups.
Those with PTE were more likely to have received
kidneys from donors with younger age and taller stature, and were less likely to have received kidneys
from donors with history of hypertension, history of
diabetes, and death from cardiovascular event. There
was no association for donor race, weight, DCD status, history of hepatitis C, or terminal serum creatinine with recipient risk of PTE (Table 1).
PTE and kidney transplant recipient outcomes

There were 4 (5%) deaths and 8 (11%) graft losses in recipients with PTE compared to 103 (10%) and 228 (22%)

respectively in the non-PTE group. PTE was not associated with increased risk of death [unadjusted HR 0.88
(0.32, 2.41)], all cause allograft failure [unadjusted HR
0.81 (0.40, 1.64)], or death censored allograft failure [unadjusted HR 0.72 (0.27, 1.98)] over the 5 year follow up
period (Table 3). As part of sensitivity analysis, we repeated this analysis by excluding the deaths and graft
failure in the first 18 months during the observation
period of development of PTE. The association of PTE
with recipient outcomes was essentially unchanged (Supplementary Table 1S).
There was no difference in the rate of hospitalization
for any cause, hospitalization due to cardiac event, or
acute rejection between the two groups (Table 4).
Recipients with PTE achieved higher estimated
glomerular filtration rate (eGFR) compared to those
without PTE at all points of follow-up within the first
24 months.
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Table 2 Comparison of choice & dose of immunosuppression regimen and use of RAAS inhibitors between subjects with and
without Post Transplant Erythrocytosis
ALL (n = 1123)

No PTE (n = 1048)

PTE (n = 75)

P-Value

928 (83%)

861 (82%)

67 (89%)

0.27

Basiliximab

163 (15%)

154 (15%)

9 (12%)

0.72

Alemtuzumab

34 (3%)

31 (3%)

3 (4%)

0.73

Rituximab

16 (1%)

15 (1%)

1 (1%)

0.86

Triple regimen with CNI, mycophenolate, and prednisone

918 (82%)

853 (81%)

65 (87%)

0.25

Tacrolimus

1075 (96%)

1000 (96%)

75 (100%)

0.17

Cyclosporine

17 (2%)

17 (2%)

0 (0%)

0.41

Mycophenolate

1086 (97%)

1014 (97%)

72 (96%)

0.52

Prednisone

956 (85%)

888 (85%)

68 (91%)

0.16

Others (Sirolimus or Everolimus or Belatacept)

6 (1%)

6 (1%)

0 (0%)

0.51

1048 (93%)

979 (93%)

69 (92%)

0.63

Medication
Induction Immunosuppression
Anti-Thymocyte Globulin

Maintenance Immunosuppression at Discharge

Maintenance Immunosuppression at Follow-up up to 1 year
Mycophenolate
Average daily mycophenolate dose (mg)

1185.9 (480.3)

1184.5 (482.9)

1205.9 (446.1)

0.86

Tacrolimus

1075 (96%)

1000 (95%)

75 (100%)

0.05

Average daily tacrolimus dose (mg)

8.0 (4.8)

8.1 (4.9)

6.6 (4.0)

0.01

Average daily tacrolimus dose (mg/kg)

0.1 (0.07)

0.11 (0.64)

0.09 (0.06)

0.03

Cyclosporine

42 (4%)

42 (4%)

0 (0%)

0.07

Prednisone

953 (85%)

886 (85%)

67 (89%)

0.26

1058 (94%)

988 (94%)

70 (93%)

0.73

Maintenance Immunosuppression at Follow-up up to 2 years
Mycophenolate
Average daily mycophenolate dose (mg)

1145.78 (435.04)

1143.26 (433.98)

1181.31 (451.47)

0.71

Tacrolimus

1078 (96%)

1003 (96%)

75 (100%)

0.06

Average daily tacrolimus dose (mg)

8.12 (22.29)

8.28 (3.09)

6.04 (3.45)

0.007

Average daily tacrolimus dose (mg/kg)

0.11 (0.28)

0.11 (0.29)

0.08 (0.05)

0.01

Cyclosporine

49 (4%)

48 (5%)

1 (1%)

0.18

Prednisone

963 (86%)

894 (85%)

69 (92%)

0.10

62 (6%)

57 (6%)

5 (7%)

0.62

Use of RAAS Inhibitors
At 3 months
At 6 months

90 (9%)

80 (8%)

10 (14%)

0.11

Anytime within 12 months

182 (16%)

164 (16%)

18 (24%)

0.05

At 18 months

171 (18%)

154 (17%)

17 (25%)

0.11

At 24 months

181 (20%)

162 (19%)

19 (27%)

0.05

Anytime within 24 months

257 (23%)

231 (22%)

26 (35%)

0.01

Continuous variables: Wilcoxon rank sum or Kruskal-Wallis tests, and categorical variables were compared with chi-square tests or Fisher exact tests
CNI Calcineurin inhibitor

Only 52% (31 out of 59) of men and 18% (3 out
of 16) of women with PTE were observed to have
persistent PTE. There was no difference in the use
of RAAS inhibitors between those with and without persistent PTE [21% versus 18% at 12 months
(p 0.64) and 35% versus 34% at 24 months (p
0.91)].

Discussion
This large multicenter study provides significant updates
to the existing knowledge in PTE. We utilized longitudinally collected data over a long follow-up period to reexamine risk factors and outcomes of PTE in the era of
modern immunosuppression, and using standardized
definitions with consideration for gender differences.
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Fig. 1 Cumulative incidence of Post Transplant Erythrocytosis by Kidney Donor Profile Index category [< 50 (n 566), >=50 (n 557)]

Earlier studies established PTE as an erythropoietindependent phenomenon [7, 11, 25, 26]. One of the key
findings of our study is the association between deceased
donor kidney quality, measured by KDPI, and risk of
PTE, such that, recipients with best quality kidneys had

the highest risk of developing PTE. This inverse association of KDPI with PTE was present across the continuum of kidney quality score. In addition, we observed
relationship between by traditional risk factors for
chronic kidney disease (CKD) in the donor, which were

Fig. 2 Event rate of Post Transplant Erythrocytosis by Kidney Donor Profile Index categories
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Table 3 Association of Post Transplant Erythrocytosis and patient & allograft survival
Outcome

Exposure

Number of
event (%)

Mean event rate per 1000
patient year (95% CI)

Unadjusted Hazard
Ratio (95% CI)

Adjusted 1 Hazard
Ratio (95% CI)

Adjusted 2 Hazard
Ratio (95% CI)

Death

No PTE (n
= 1048)

103 (10%)

23.5 (19.4, 28.5)

1 (ref)

1 (ref)

1 (ref)

PTE (n =
75)

4 (5%)

18.4 (6.9, 48.9)

0.88 (0.32, 2.41)

1.01 (0.50, 2.07)

1.07 (0.52, 2.20)

No PTE (n
= 1048)

228a (22%)

52.0 (45.6, 59.2)

1 (ref)

1 (ref)

1 (ref)

PTE (n =
75)

8 (11%)

36.7 (18.4, 73.4)

0.81 (0.40, 1.64)

1.07 (0.39, 2.94)

1.29 (0.46, 3.63)

No PTE (n
= 1048)

131 (12%)

29.9 (25.2, 35.4)

1 (ref)

1 (ref)

1 (ref)

PTE (n =
75)

4 (5%)

18.4 (6.9, 48.9)

0.72 (0.27, 1.98)

0.94 (0.35, 2.60)

0.94 (0.34, 2.60)

All-cause graft
failure

Death-censored
graft failure

Adjusted 1 is adjusted for donor Kidney Donor Profile Index (KDPI)
Adjusted 2 is adjusted for donor KDPI, cold ischemia time and the following recipient variables: age (years), black race, sex, previous kidney transplant, number of
human leukocyte antigen mismatches, panel reactive antibody (%), body mass index (kg/m2), preemptive transplant and transplant center
a
There were 6 recipients who developed graft failure and then died. This explains the difference between the number of all-cause graft failure (228) and the sum
of numbers of death (103) and death-censored graft failure (131)

age, diabetes, hypertension, and cerebrovascular disease
with reduced occurrence of PTE. These findings suggest
that clinical risk factors may lead to reduced sensitivity
of erythropoietin-producing fibroblasts in the renal cortex before developing clinically evident CKD.
RAAS inhibitors have been shown to be effective in
the treatment of PTE and therefore are used as first-line

therapy [7, 10, 27–31]. Although our study showed that
recipients with PTE were more likely to be on RAAS inhibitors, these agents remained underutilized as a significant proportion of patients with PTE were not receiving
them. This could be due to under recognition of this
phenomenon by using older non-standardized definitions, non-familiarity with the new definition, or due to

Table 4 Association of Post Transplant Erythrocytosis and selected Kidney Transplant outcomes
all (n = 1123)

No PTE (n = 1048)

PTE (n = 75)

P-value

6 months

602 (54%)

568 (54%)

34 (45%)

0.70

12 months

682 (61%)

641 (61%)

41 (55%)

0.26

18 months

718 (64%)

674 (64%)

44 (59%)

0.32

24 months

743 (66%)

698 (67%)

45 (60%)

0.24

Follow-up Point
Cumulative Hospitalizations

Cumulative Hospitalizations due to Cardiovascular Event
6 months

22 (2%)

22 (2%)

0 (0%)

0.20

12 months

33 (3%)

32 (3%)

1 (1%)

0.39

18 months

41 (4%)

39 (4%)

2 (3%)

0.63

24 months

50 (4%)

48 (5%)

2 (3%)

0.43

Cumulative Episodes of Rejection
6 months

93 (8%)

90 (9%)

3 (4%)

0.16

12 months

118 (11%)

113 (11%)

5 (7%)

0.26

18 months

133 (12%)

128 (12%)

5 (7%)

0.15

24 months

144 (13%)

139 (13%)

5 (7%)

0.09

6 months

51.4 (20.4)

50.81 (20.43)

60 (18.17)

< 0.001

12 months

52.3 (20.4)

51.67 (20.44)

61.85 (18.57)

< 0.001

18 months

52.8 (20.3)

52.17 (20.34)

62.04 (17.81)

< 0.001

24 months

52.8 (21.3)

51.99 (21.21)

62.86 (20.37)

< 0.001

Estimated GFR

Continuous variables: Wilcoxon rank sum or Kruskal-Wallis tests, and categorical variables were compared with chi-square tests or Fisher exact tests
GFR Glomerular filtration rate
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contraindications for using RAAS inhibitors. It is worth
mentioning that the criteria for erythrocytosis was revised in 2016, several years after DDS cohort was established. Interestingly, only about half of the patients with
PTE continued to have persistent elevation in
hemoglobin over the follow-up period, and there was no
difference in RAAS inhibitors use between the persistent
and non-persistent groups.
Concerning PTE impact on transplant outcomes, our
study showed that those with PTE did not achieve superior patient or allograft survival over a follow-up
period of 5 years despite having better kidney quality,
therefore, arguing the possibility that PTE may mitigate
the expected favorable outcomes of receiving a higherquality kidney. It is worth recalling here that a previous
study by Kiberd et al. showed that recipients with PTE
achieved superior overall survival but had inferior renal
allograft survival [5]. We did not observe inferior renal
allograft outcome in our study, and one may hypothesize
that the advancement in immunosuppression and medical management of transplant recipients have outweighed the possible negative impact of PTE. PTE has
been traditionally associated with increased risk of
thromboembolic and cardiovascular events such as
stroke and myocardial infarction. The reported incidence
of these events is variable depending on the study and
duration of follow-up, but it ranged between 10 and 40%
[1, 9, 32, 33]. Nonetheless, our study did not show increased risk for mortality, overall hospitalizations, or
hospitalization due to cardiovascular events.
Our study is the first to assess the natural course of
PTE using the updated WHO criteria to define erythrocytosis with lower hemoglobin thresholds in a multicenter seting [15]. Despite that, the incidence of PTE
was only 6.6% in the first 5 years following KT, which is
lower than previously reported. Earlier studies reported
incidence rates between 8 and 20% [1, 2, 8, 9, 11, 28,
34]. Kiberd et al. compared the incidence of PTE between 1993 and 1996 and 1997–2005 and observed a declining incidence rate from 18.7 to 8.1%. This lower
trend is more consistent with our study and could be explained by the adoption of more potent myelosuppressive agents such as anti-thymocyte globulin [rabbit] and
mycophenolate for immunosuppression. However, we
did not observe a difference in mycophenolate dose between PTE and non-PTE groups. In contrast, our study
showed that patients with PTE received lower average
daily doses of tacrolimus compared to those without
PTE during follow-up. Anemia is a reported side effect
of tacrolimus, and one may hypothesize that the widespread use of tacrolimus in the last two decades has contributed to the overall declining incidence of PTE. It is
also possible that lack of live donor kidney transplant recipients contributed to the low incidence of PTE in our
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study although the association of PTE with receiving live
donor kidneys has not been reported in prior studies.
Consistent with previous studies, we found an association between PTE and recipient sex, renal allograft
function, and end-stage renal disease due to polycystic
kidney disease [1, 2, 6, 9, 12, 34]. Our study also demonstrated an association of recipient age, race, and BMI
with PTE. In contrast to original observations, we did
not find an association between PTE and recipient history of diabetes [1], history of hypertension [1, 11], duration of dialysis [9], renal allograft rejection [1, 6], or use
of mammalian target of rapamycin (mTOR) inhibitors
[4]. We were unable to assess for potential relationships
between PTE and retention of native kidneys [11], diuretic use [11], or tobacco use [1], which have been reported in previous studies.
Some limitations exist in the current study. All patients in this cohort were recipients of deceased-donor
kidney transplants which limit generalizability to living
donor kidney transplant recipients. We could not assess
rates of certain PTE-related complications such as
thromboembolic events because the occurrence of these
events was not systematically collected during follow-up.
For the same reason, the presence of secondary causes
of PTE such as tobacco use, malignancy, lung disease,
sleep apnea, and renal artery stenosis were not assessed.
Other therapies that have been traditionally used as second line treatments for PTE such as therapeutic phlebotomy [35], and theophylline [36], as well as the
presence of contraindications to using RAAS inhibitors
were not evaluated.
In conclusion, our study demonstrated a low incidence of
PTE in the current era of immunosuppression and an association between PTE and quality of donated kidneys. This association is driven by traditional risk factors for chronic kidney
disease in the donor. Despite the low incidence, the
underutilization of RAAS inhibitors in patients with PTE
raises the possibility of under-recognition of this phenomenon.
We could not demonstrate any associations between PTE and
recipient outcomes, but lack of improved graft survival in recipient receiving higher quality kidneys is concerning. Our
findings need to be confirmed in larger cohorts to allow for
improved recognition and management of PTE.
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